Cancer research facility
The London Cancer Hub for Cancer Research and Treatment in Sutton will be developed by the Institute of Cancer Research (ICR) in collaboration with The Royal Marsden NHS Foundation Trust, the Greater London Authority, Epsom, and St. Helier University Hospitals NHS Trust.
Plans were unveiled in February 2016 and the facility is expected to help develop at least two extra cancer drugs every five years.
Construction is planned to be initiated in 2018 and is expected to generate 7,000 jobs in the areas of research, healthcare, administration, and leisure. It will also offer employment to 6,200 people during construction.
The project is expected to generate approximately £5m ($6.40m) in revenue a year and will contribute £1.1bn to the UK economy.
The cancer hub will be located on 20ha of residential area situated to the south of Sutton town centre in the Golden Triangle cluster with universities, researchers, and life science companies.
The hub will be situated in close proximity to Gatwick and Heathrow airports. It will be 30 minutes away from the Royal Surrey Hospital and the Cancer Partnership Research group located in Surrey.
The new state-of-the-art facility will have integrated lifescience buildings with a total floor space of 280,000ft², accommodating cancer research and diagnosis facilities.
It will accommodate approximately 10,000 scientists and clinical support staff, as well as provide space for research and development in biotech, pharmaceutical, and equipment manufacturers.
The hub will also help expand the world-leading cancer research and treatment carried out at the ICR and The Royal Marsden.
The hub will also include classrooms, hotels for visitors and patients, and leisure amenities. New buildings will enhance research and cancer care, offering an environment for interaction between scientists and clinicians.
The main entrance to the hub will be located on the north-west corner and will connect to the ICR campus. The west to east route will connect Brighton Road and a north-south link road will connect to the main clinical area. A transport loop will be aligned to ICR buildings and amenity areas.
The facility will comprise public squares, open spaces, and landscaping. The hub will also include public transport facilities and dedicated parking spaces for cars and bicycles.
The project will be developed over a period of 20 years in five phases. ICR will expand new drug discovery facilities in the research hub complex in the first phase of development. It will also build and expand parking spaces, a power plant, and a life sciences school by 2018.
Sutton Council has purchased 22,000m² of land for the first stage of a planned expansion and redevelopment.
The second phase of development will include construction of two public squares for business and community activities. The Royal Marsden will expand the medical care facilities by 2019.
The third phase of development will include provision of facilities for private enterprises for activities related to leisure and relaxation.
A tram network will be developed in the fourth phase to link the hub to Sutton town and central London from the west. The fourth phase will also involve construction of life-science buildings with space for academic research and medical facilities.
The fifth phase of the research hub development will include integrated life-science facilities to pool researchers and clinicians to work at one location.
Haptic Architects and Nordic in partnership with Inner Circle Consulting, WSP, and JLL created the development framework for the cancer hub in London.
The total investment estimated for the completion of the project is £1bn ($1.28bn). Sutton Council received £300,000 from the UK Government in November 2016 towards the project’s development.
Sutton Council provided £14m ($17.92m) for the cancer hub in March 2017.
Lonza announced the expansion of its bioconjugation facility at its Visp site in Switzerland in December 2020. The expansion will…
Merck announced the expansion of its high-potent active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) production capabilities and capacity at…
Alnylam Pharmaceuticals is constructing a new drug substance manufacturing and cGMP warehouse facility in Norton, Massachusetts, US. The company broke…
POINT Biopharma, a clinical-stage biopharmaceutical company, is planning to construct its first US manufacturing plant in Indianapolis, Indiana. The investment…